Adaptive Biotechnologies CorporationADPT
ASignal's systematic analysis rates ADPT as Bullish. Adaptive Biotechnologies Corporation has a market cap of $2.70B, a -16.8% net margin, and 35.1% year-over-year revenue growth.
Reflects the latest available analysis · analyzed Jun 7, 2026
The case on ADPT
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong revenue growth (35.1% YoY)
- Positive free cash flow ($16.1M)
- Low debt-to-equity ratio (0.93x)
- High cash position relative to debt
- MACD above signal line indicating bullish momentum
- Price trading above 20-day and 50-day moving averages
- RSI at 76.46 indicating overbought conditions
- Negative operating and net margins
- Negative ROE and ROA
- Negative EV/EBITDA and forward P/E suggesting valuation uncertainty
- Lack of Reddit retail sentiment data
Key facts
See the full verdict on ADPT
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes ADPT
Most investors never get a second opinion, let alone several. ASignal runs ADPT past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.